Terns Pharmaceuticals, INC. (TERN) — 8-K Filings

8-K Filings (18)

• Terns Pharma Enters Material Definitive Agreement — Mar 25, 2026
  Terns Pharmaceuticals, Inc. filed an 8-K on March 25, 2026, reporting an "Entry into a Material Definitive Agreement" as of March 24, 2026. This indicates the c
• Terns Pharmaceuticals Files 8-K — Dec 11, 2025 Risk: medium
  Terns Pharmaceuticals, Inc. filed an 8-K on December 11, 2025, reporting an event that occurred on December 9, 2025. The filing is categorized under 'Other Even
• Terns Pharmaceuticals Files 8-K — Dec 8, 2025 Risk: low
  On December 8, 2025, Terns Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is providing information related to Regulation FD Di
• Terns Pharmaceuticals Files 8-K — Nov 3, 2025 Risk: low
  Terns Pharmaceuticals, Inc. filed an 8-K on November 3, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures,
• Terns Pharmaceuticals Files 8-K — Oct 22, 2025 Risk: low
  Terns Pharmaceuticals, Inc. filed an 8-K on October 22, 2025, reporting on events that occurred on October 21, 2025. The filing pertains to 'Other Events' and '
• Terns Pharmaceuticals Reports Shareholder Vote Matter — Jun 16, 2025 Risk: medium
  Terns Pharmaceuticals, Inc. filed an 8-K on June 16, 2025, reporting on a matter submitted to a vote of its security holders on June 11, 2025. The filing does n
• Terns Pharmaceuticals Appoints New Director — Feb 24, 2025 Risk: low
  Terns Pharmaceuticals, Inc. announced on February 22, 2025, a change in its board of directors. Specifically, Dr. Andrew A. Adams has been appointed as a Class
• Terns Pharmaceuticals Files 8-K on Executive Changes — Feb 20, 2025 Risk: medium
  Terns Pharmaceuticals, Inc. filed an 8-K on February 20, 2025, reporting on the departure of directors or certain officers, election of directors, appointment o
• Terns Pharmaceuticals Announces Executive Changes and New Director — Feb 6, 2025 Risk: medium
  Terns Pharmaceuticals, Inc. announced on February 1, 2025, the departure of its Chief Medical Officer, Dr. Sarah Johnson, effective immediately. The company als
• Terns Pharmaceuticals Files 8-K — Dec 3, 2024 Risk: low
  On December 3, 2024, Terns Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events, with no
• Terns Pharmaceuticals Relocates Principal Executive Offices — Nov 18, 2024 Risk: low
  Terns Pharmaceuticals, Inc. announced on November 14, 2024, a change in its principal executive offices to 1065 East Hillsdale Blvd., Suite 100, Foster City, Ca
• Terns Pharmaceuticals Files 8-K — Sep 12, 2024 Risk: low
  Terns Pharmaceuticals, Inc. filed an 8-K on September 12, 2024, reporting an event on September 10, 2024. The filing primarily concerns financial statements and
• Terns Pharmaceuticals Files 8-K — Sep 9, 2024 Risk: low
  Terns Pharmaceuticals, Inc. filed an 8-K on September 9, 2024, reporting on other events and financial statements. The filing does not contain specific details
• Terns Pharmaceuticals Appoints New Director — Jul 29, 2024 Risk: low
  Terns Pharmaceuticals, Inc. announced on July 23, 2024, a change in its board of directors. Specifically, Dr. David J. Earp has been appointed as a new Class II
• Terns Pharmaceuticals Enters Loan Agreement — Jul 3, 2024 Risk: medium
  On July 1, 2024, Terns Pharmaceuticals, Inc. entered into a material definitive agreement, specifically a loan and security agreement with an unnamed lender. Th
• Terns Pharmaceuticals Files 8-K on Shareholder Vote — Jun 12, 2024 Risk: low
  Terns Pharmaceuticals, Inc. filed an 8-K on June 12, 2024, reporting on matters submitted to a vote of security holders on June 10, 2024. The filing details the
• Terns Pharmaceuticals Files 8-K — Apr 29, 2024 Risk: low
  Terns Pharmaceuticals, Inc. filed an 8-K on April 29, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
• Terns Pharma 8-K: Leadership Changes & Comp Arrangements — Feb 7, 2024
  Terns Pharmaceuticals, Inc. filed an 8-K on February 7, 2024, reporting an event that occurred on February 6, 2024. This filing, under Item 5.02, pertains to ch

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX